NCT05495321View on ClinicalTrials.gov

Interleukin-2 on Active Dermatomyositis

PHASE3Enrolling by invitationINTERVENTIONAL
Enrollment

240

Participants

Timeline

Start Date

December 1, 2022

Primary Completion Date

September 1, 2025

Study Completion Date

September 1, 2026

Conditions
Dermatomyositis
Interventions
DRUG

Interleukin-2

low dose interleukin-2 injected subcutaneously, at a dose of 1 x 10\~6 IU once every other day, for 6 months.

Trial Locations (1)

100044

Peking university people's hospital, Beijing

All Listed Sponsors
lead

Peking University People's Hospital

OTHER